GLP-1 receptor agonist as a modulator of innate immunity

Front Immunol. 2022 Dec 8:13:997578. doi: 10.3389/fimmu.2022.997578. eCollection 2022.

Abstract

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid hormone secreted by L cells in the distal ileum, colon, and pancreatic α cells, which participates in blood sugar regulation by promoting insulin release, reducing glucagon levels, delaying gastric emptying, increasing satiety, and reducing appetite. GLP-1 specifically binds to the glucagon-like peptide-1 receptor (GLP-1R) in the body, directly stimulating the secretion of insulin by pancreatic β-cells, promoting proliferation and differentiation, and inhibiting cell apoptosis, thereby exerting a glycemic lowering effect. The glycemic regulating effect of GLP-1 and its analogues has been well studied in human and murine models in the circumstance of many diseases. Recent studies found that GLP-1 is able to modulate innate immune response in a number of inflammatory diseases. In the present review, we summarize the research progression of GLP-1 and its analogues in immunomodulation and related signal pathways.

Keywords: glucagon-like peptide-1; immunomodulation; inflammatory diseases; liraglutide; signal pathways.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose
  • Glucagon-Like Peptide 1 / metabolism
  • Glucagon-Like Peptide-1 Receptor*
  • Humans
  • Immunity, Innate
  • Insulin* / metabolism
  • Mice

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Insulin
  • Glucagon-Like Peptide 1
  • Blood Glucose